Ambrx Biopharma Inc (AMAM)

[Hercules1]

it was well on its way when it hit $2.50.

then some group decided to flip it.

of course it is being shorted to death also.

but this news is too big:

they have a multi billion dollar drug:

and 100% disease control. it doesnt get any better than this:


The preliminary results showed a 51.7% overall response rate (ORR) and 100% disease control rate (DCR) following treatment with ARX788. Additionally, no drug-related serious adverse events (SAEs) were noted by any patients.

With investors reacting the way they did, it’s safe to say they were impressed with the results; considering how big the breast cancer market is, the drug’s potential has caused a bit of a stir.